No abstract

Results. Serum 25-hydroxyvitamin D [25(OH)D]was 37 nmol L )1 or less in 70% of female and in 61% of male inpatients and in 44% of female and in 37% of male outpatients. In the whole population, a statistically signi®cant inverse association (P < 0.0001) was detected between iPTH and 25(OH)D levels; the iPTH concentration appeared to start increasing when 25(OH)D concentration was 50 nmol L )1 or less. The association remained the same (P < 0.0001) when FDI was used instead of 25(OH)D in the calculations. When the sexes were analysed separately, the statistically signi®cant association was found only in females (P < 0.0001 for iPTH versus 25(OH)D; P < 0.0001 for iPTH versus FDI) but not in males. Conclusion. Hypovitaminosis D is very common amongst Finnish in-and outpatients in both sexes, causing secondary hyperparathyroidism in females. More extensive studies are warranted to elucidate the vitamin D status of the Finnish population.

No abstract

No abstract

Type I tyrosinemia (HTI) is an autosomally recessively inherited disease caused by deficiency of fumarylacetoacetate hydrolase. The disease manifests with liver failure, renal tubular defects, and neurologic crises. Currently orthotopic liver transplantation (OLT) enables patients to survive. However, renal fumarylacetoacetate hydrolase deficiency is not corrected by OLT, and the long-term prognosis of the nephropathy is not known. We investigated tyrosine metabolism, GFR, renal tubular function, and histopathology before and 18-36 mo after OLT in eight patients with HTI. Progressive renal dysfunction was not documented despite continuing, although diminished, urinary succinylacetone excretion in all patients. The mean GFR was 82 mL/min/1.73 m 2 before and 102 mL at 18 mo and 93 mL at 36 mo after OLT. All patients showed tubular dysfunction before OLT. At 18 mo, glucosuria occurred in one, amino aciduria and phosphaturia in three, and hypercalciuria in six patients. Only hypercalciuria was seen at 36 mo. Renal biopsies showed mild Type I tyrosinemia is an autosomally recessively inh erited disease caused by FAR deficiency (1). FAR catalyzes the last step of tyrosine metabolism, and the deficiency leads to the accumulation of maleyl-and fumaryl acetoacetate and to the appearance of SA and SAA. Increased urinary excretion of SA and SAA occurs only in tyrosinemia and is diagnostic for the disease. The gene coding for FAR has been assigned to chromosome 15q23-q25 (2). Seven separate disease-inducing mutations of the gene have been described (3-6).Clinically type I tyrosinemia can be divided into two forms. The acute form of the disease is ch aracterized by signs of severe liver failure-ascites, bleeding tendency, and hypoglycemia-from the first months of life , and previously the patients died in early infancy. The chronic form is milder, and liver function less abnormal. However, the risk of hepatocellular carcinoma is increased, and carcinoma has been estimated